Iaso Ventures, founded in 2019 and based in Boston, Massachusetts, is a pioneering venture capital firm that concentrates on the behavioral and neurological health sector. As the first of its kind in the nation, it aims to support life sciences and health technology startups predominantly within the United States. By targeting innovative companies in these critical areas, Iaso Ventures seeks to advance solutions that address pressing health challenges. The firm emphasizes a strategic approach to investment, focusing on fostering growth in the behavioral and neurological health landscape.
Catena Biosciences is a biotechnology startup emerging from research at UC Berkeley, focused on developing innovative treatments for autoimmune disorders. The company has created an advanced protein coupling technology that allows for the rapid and selective fusion of proteins using natural amino acids, specifically tyrosine and cysteine. This method enhances the ability of researchers to design novel therapeutics not only for autoimmune disorders but also for oncology and vaccine development. By leveraging this unique platform, Catena Biosciences aims to transform the landscape of treatment options for these challenging medical conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.